



## Glucose Metabolism: Molecular Basis and Novel Therapies of Diabetic Complication

Guest Editors:

**Prof. Dr. Hendrik Lehnert**

1. Department of Internal  
Medicine I, University of Lübeck,  
Lübeck, Germany  
2. Rektorat, Paris Lodron  
Universität Salzburg, Salzburg,  
Austria

**Prof. Dr. Sebastian M.  
Meyhöfer**

1. Institute of Endocrinology and  
Diabetes, University of Lübeck, D-  
23538 Lübeck, Germany  
2. German Center of Diabetes  
Research, D-85764 Neuherberg,  
Germany

Deadline for manuscript  
submissions:  
**closed (31 December 2023)**

### Message from the Guest Editors

Dear Colleagues,

Sebastian Meyhoefer and I are delighted to invite you to contribute a manuscript for a Special Issue of *Biomedicines*.

The title of this issue will be Glucose Metabolism: Molecular Basis and Novel Therapies of Diabetic Complications and it will address important topics such as the genetic and phenotypic heterogeneity of diabetes as an underlying mechanisms for differential complications settings, the mechanistic basis for disturbed hypoglycemia awareness and cognitive defects, the causal link between diabetes and tumorigenesis or the impact on lipid metabolism and cardiovascular sequelae.

We are convinced that this issue will shed further our knowledge on the mechanistic basis of diabetic complications and will also improve our understanding of how to therapeutically tackle these problems, based on a personalized approach that takes the heterogeneity of diabetes into account.

We are very much looking forward to receiving your contribution,

With warm regards

Prof. Dr. Hendrik Lehnert

Prof. Sebastian M. Meyhoefer

Guest Editors



[mdpi.com/si/168239](https://mdpi.com/si/168239)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)